Alisha H. Bent, M.D.

Peer-Reviewed Articles

1. Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol 10(11):1519-1529, 2025. e-Pub 2025. PMID: 39264607.
2. Cohen SA, Aushev VN, Laliotis G, Jabbal IS, Nagarajan A, Wang C, Fakih M, Sharif S, Alyunis F, Tejani MA, Alqahtani A, Marshall J, Chang J, Botta G, Manage K, George GV, Sharma S, Malhotra M, Chandana S, Mehler S, Somer BG, Babadi E, Wu C, Hanna D, Chidharla A, Kasi A, Vosoughi E, Dayyani F, Pedersen K, Briski RE, Azzi G, Katiyar V, Chan A, Sharma V, Shreenivas A, Chakrabarti S, Fuqua J, Malla M, Polite B, Bent AH, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Kopetz S. Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer. Ann Surg. e-Pub 2025. PMID: 40772634.
3. Morris VK, Xiao W, Lin K, Wong CW, Wotman MT, Holliday EB, Huey RW, Noticewala SS, Ludmir EB, Bent AH, Ludford K, Messick C, Koay EJ, Smith G, Konishi T, Bednarski B, Chang GJ, Koong AC, You Y, Das P, Gillison ML. Time Dependency for Human Papillomavirus Circulating Tumor DNA Detection after Chemoradiation as a Prognostic Biomarker for Localized Anal Cancer. Clin Cancer Res 31(12):2399-2405, 2025. e-Pub 2025. PMID: 39873618.
4. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist 28(12):e1303-e1305, 2023. e-Pub 2023. PMID: 37738316.
5. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
6. Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022. e-Pub 2022. PMID: 35450837.
7. Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, Timmerman R, Brugarolas J. Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clin Genitourin Cancer 17(2):e263-e272, 2019. e-Pub 2019. PMID: 30538068.
8. Buran TJ, Sandhu AK, Azeredo AM, Bent AH, Williamson JG, Gu L. Effects of exogenous abscisic acid on fruit quality, antioxidant capacities, and phytochemical contents of southern high bush blueberries. Food Chem 132(3):1375-1381, 2012. e-Pub 2012. PMID: 29243625.
9. Bent A, Parseghian C, Morris VK, Higbie V, Eluri M, Kee BK, Huey RW, Willis J, Morelli MP, Haldar S, Martinez SA, YC Shen JP, Singh Raghav KP, Overman MJ, Horodecky K, Alfaro K, Aziz K, Kell RJ, Kopetz S, Dasari A. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort. 2026 ASCO Gastrointestinal Cancers Symposium 44.

Review Articles

1. Pellatt AJ, Barnett RM, Gnerre S, Edwards K, Willis JA, Overmann MJ, Raghav K, Parseghian CM, Dasari A, Morelli MP, Bent A, Eluri M, Hornstein N, Drusbosky LM, Kopetz S, Morris VK. Detection of oncogenic fusions in colorectal cancer using a partner-agnostic next-generation sequencing approach. BMC Cancer 25(1):1201, 2025. e-Pub 2025. PMID: 40696295.
2. Pellatt AJ, Bent A, Hornstein N, Parseghian C, Huey R, Raghav K, Morris V, Overman M, Morelli P, Willis J, Le P, Shen JP, Kee B, Eluri M, Higbie V, Alfaro-Munoz K, Aziz K, Kell R, Sun R, Kopetz S, Dasari A. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT. JCO Precis Oncol 9, 2025. e-Pub 2025. PMID: 40669021.

Other Articles

1. Bent A, Dasari A, Smith J Are We There Yet? The Telltale Trail of ctDNA in Rectal Cancer. Clin Cancer Res 31(24):5117-5119, 2025. PMID: 41114665.
2. Kopetz, S, Bent, AH Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays. Clin Cancer Res 27(20), 2021. PMID: 34389607.

Abstracts

1. Allam J, Estrella J, Higbie V, Le P, Bent AH, Kotlov N, Baranov O, Tongsai F, Paradiso F, Samarina N, Galanicheva N, Hensley M, Fowler NH, Willett A, Nguyen V, Matamoros A, Lano EA, Singh Raghav KP, Huey RW. Uncovering the tumor microenvironment (TME): Exploring survival and immunotherapy (IO) response in cancer of unknown primary (CUP). J Clin Oncol 43(16), 2025. e-Pub 2025.
2. Pan K, Baig Y, Willis J, Dasari A, Bent AH, Higbie V, Huey RW, Kee BK, Lee MS, Parseghian C, Morelli MP, YC Shen JP, Kopetz S, Van K Morris II. Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies. J Clin Oncol 43(4), 2025. e-Pub 2025.
3. Huey RW, Singh Raghav KP, Estrella J, Higbie V, Le P, Bent AH, Matamoros A, Lano EA, Willett A, Nguyen V, Escano M, Wilson KF, Lin HY. Phase II trial of sintilimab in cancer of unknown primary. J Clin Oncol 43(4), 2025. e-Pub 2025.
4. Wainberg ZA, Bent AH, Moreno V, Pedregal M, Mehta R, Chen EX, Patino JL, Moy RH, Madajewski B, Petrone A, Adesara-Patel P, Liu Y, Sun X, Aguado-Fraile E, Basciano PA, Sethuraman S, Hawkey N, Fontana E. 504MO Phase I study of the PKMYT1 inhibitor lunresertib (lunre) in combination with FOLFIRI in advanced gastrointestinal (GI) cancers (MINOTAUR study) 35(1):S201, 2024. e-Pub 2024.
5. Van K Morris II, Xiao W, Holliday EB, Lin K, Huey RW, Noticewala SS, Ludmir EB, Bent AH, Higbie V, Koay EJ, Koong AC, Das P, Gillison ML. Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer. J Clin Oncol 42(16), 2024. e-Pub 2024.
6. Pellatt AJ, Maddalena G, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. Redefining the prognostic significance of RAS and BRAF V600E mutations on disease free survival in patients with colorectal cancer in the era of ct-DNA defined minimal residual disease: Results from the MD Anderson INTERCEPT Program. J Clin Oncol 42(3), 2024. e-Pub 2024.
7. Higbie V, Shah P, Bent AH, Dasari A, Huey RW, Johnson B, Kee BK, Kopetz S, Lee MS, Ludford K, Morelli MP, Morris VK, Parseghian CM, Singh Raghav KP, YC Shen JP, Willis J, Wolff RA, Overman MJ. Natural history and patterns of progression for dMMR/MSI-H colorectal cancer treated with immune checkpoint blockade: A single center retrospective analysis. J Clin Oncol 42(3), 2024. e-Pub 2024.
8. Maddalena G, Pellatt AJ, Eluri M, Parseghian CM, Aziz K, Alfaro K, Kell RJ, Bent AH, Huey RW, Uppal A, Konishi T, Overman MJ, Morelli MP, Willis J, YC Shen JP, Singh Raghav KP, Newhook TE, Morris VK, Dasari A, Kopetz S. INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort. J Clin Oncol 42(3), 2024. e-Pub 2024.
9. Dasari A, Bent A, Alfaro-Munoz K, Huey R, Johnson B, Lee M, Morelli MP, Morris V, Overman M, Parseghian C, Raghav K, Shen J, Willis J, Newhook T, Uppal A, You Y, Konishi T, Chang G, Kopetz S, Wolff R. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. J Clin Oncol 41(16), 2023. e-Pub 2023.
10. Bent AH, Maru DM, Vauthey J, Dasari A, Johnson B, Kee BK, Parseghian CM, Menter D, Overman MJ, Morris VK, Fan P, Koyama K, Maeda N, Kopetz S, Singh Raghav KP. HER3 expression in metastatic colorectal cancer: Defining the clinicomolecular profile of an emerging target. J Clin Oncol 40(16), 2022. e-Pub 2022.
11. Payapwattanawong S, Osterlund E, Vetere G, Bent AH, Dasari A, Kee BK, Parseghian C, Willis J, YC Shen JP, Singh Raghav KP, Eluri M, Morelli MP, Overman MJ, Le P, Huey RW, Martinez SA, Higbie V, Shen X, Morris VK, Kopetz S. Aspirin use and PI3K mutations in metastatic colorectal cancer (mCRC). 2026 ASCO Gastrointestinal Cancers Symposium 44.
12. Bof F, Maddalena G, Morris VK, Parseghian C, Higbie V, Eluri M, Morelli MP, YC Shen JP, Huey RW, Willis J, Kee BK, Haldar S, Martinez SA, Lonardi S, Bergamo F, Singh Raghav KP, Dasari A, Overman MJ, Kopetz S, Bent AH. Cracking the code: Clinical predictors of brain metastases in colorectal cancer. 2026 ASCO Gastrointestinal Cancers Symposium 44.
13. Morelli MP, Basar R, Marin D, Zeller BE, Willis J, Kee BK, Jacob S, Diao S, Huey RW, Morris VK, Bent AH, Haldar S, Nurmammadova A, Bohat R, Menter D, Overman MJ, Shen X, Kopetz S, Shpall EJ, Rezvani K. Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD). 2026 ASCO Gastrointestinal Cancers Symposium 44.
14. Ascencio YO, Lin K, Peddireddy A, You Y, Willis J, Smith JJ, Smith GL, Noticewala SS, Messick C, Le P, Huey RW, Holliday E, Higbie V, Eluri M, Das P, Chang GJ, Bent AH, Chiao EY, Ludford K, Morris VK. Outcomes for incurable anal cancer according to HIV status. 2026 ASCO Gastrointestinal Cancers Symposium 44.

Book Chapters

1. Parseghian CM, Bent AH. Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. In: Colorectal Liver Metastasis. Springer Nature, 293-299, 2022.